問卷

TPIDB > Search Result

Search Result

篩選

List

5Cases

2025-11-01 - 2033-12-31

Phase III

Not yet recruiting
A phase III, open-label, randomized, multicenter, parallel-group trial evaluating the efficacy and safety of first-line trastuzumab deruxtecan combined with rilvegostomig or volrustomig versus pembrolizumab plus chemotherapy in locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous NSCLC (DESTINY-Lung07).
  • Condition/Disease

    Locally advanced unresectable or metastatic HER2-overexpressing non-squamous non-small cell lung cancer

  • Test Drug

    Trastuzumab Deruxtecan(AZD4552 DS-8201A)

Participate Sites
9Sites

Recruiting9Sites

2026-03-16 - 2031-11-30

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2026-03-16 - 2029-01-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting2Sites

Recruiting10Sites

2025-10-01 - 2035-01-20

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2028-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites